SYDNEY: Asian share markets were mostly firmer on Monday, as Wall Street futures started the week with gains on hopes for an upbeat earnings season, while easing oil prices promised relief from inflationary pressures.

While there were no new developments in the fractious U.S.-Iran peace talks, ships are passing through the Strait of Hormuz with 160 vessels reported from Monday to Saturday last week.

OPEC+ also agreed a further increase in output targets by 188,000 barrels per day from August, on top of similar increases for June and July. As a result, Brent slipped 0.6% to near four-month lows at $71.70 a barrel and U.S. crude ‌lost 0.5% to $68.38. [O/R]

The cooling ⁠in energy ⁠costs combined with a softer U.S. payrolls report, led markets to scale back the risk of a Federal Reserve rate hike in the near term, with futures implying a 78% chance of a steady outcome at the July 29 meeting.

Minutes of the Fed’s last meeting are due on Wednesday and should offer colour on the hawkish turn by some board members, though that preceded the recent slide in oil.

“Even if you thought there was a risk the Fed might move soon, I think we’re safe at least for another month,” said Richard Yetsenga, head of research at ANZ.
“Our view overall still is the Fed won’t do anything, but clearly we’ve been above target on the Fed’s preferred inflation measure ⁠for five years,” ‌he added. “There is some risk that the Fed just runs out of patience.” The diminished risk of a hike this month should allow investors to focus on the looming earnings season, where the AI boom is set to deliver bumper tech ⁠profits.

This week has just Delta Air Lines and PepsiCo as tasters, though Samsung Electronics is set to make a splash on Tuesday as analysts expect an 18-fold increase in profits.

PROFIT BONANZA FOR CHIPMAKERS
The world’s largest memory chipmaker by sales is likely to flag an operating profit of 86 trillion won ($56.35 billion) for the April to June quarter, according to an LSEG SmartEstimate.

South Korea’s red hot market cooled a little last week but is still up 92% for the year so far as AI demand and tight supplies boost chip prices. The index added another 2.25% on Monday, while Japan’s Nikkei eased 0.1%.

MSCI’s broadest index of Asia-Pacific shares outside Japan gained 0.4%.

In Europe, EUROSTOXX 50 futures were flat, while DAX futures rose 0.2% and FTSE futures fell 0.2%. S&P ‌500 futures firmed 0.5%, while Nasdaq futures climbed 1.4% on top of a 2.1% gain last week.

The data calendar kicks off with the U.S. ISM Services survey later on Monday where forecasts favour a slight pullback to a still-healthy 54.0 in June.

A clutch of central bankers are speaking at ⁠an ECB conference later in the day, including Fed Board Governor Christopher Waller, while ECB President Christine Lagarde is also due to speak in Paris.

New Zealand’s central bank is due to meet on Wednesday and markets are wagering it will raise its 2.25% cash rate by a quarter point, the first hike since mid-2023.

Policy makers have foreshadowed a tightening for some time, though again that was before the tumble in oil prices and there has to be a chance it will surprise by holding rates steady.

In currency markets, the dollar index had steadied at 100.880 after dipping in the wake of the disappointing June payrolls report. The euro was flat at $1.1445, just above the recent 13-month low of $1.1325.

The dollar held at 161.45 yen, not far from 40-year peaks of 162.84 as speculators remain wary of Japanese intervention.

In commodity markets, gold was little moved at $4,177 an ounce, having bounced 2% last week. [GOL/]

This week’s $29 billion US stock-market listing for SK Hynix may be the biggest-ever first-time share sale by a foreign company, but it isn’t just about raising cash. It’s also about competing in the hottest corner of the global stock market-memory chips used in AI computing.

For years, the South Korea-based semiconductor manufacturer has traded at a discount to its chief US-based rival, Micron Technology.

Tapping into the world’s deepest equity market and its frenzy for all things related to artificial intelligence could help change that at a time when the companies that make memory chips and other equipment used in AI data centres are driving the performance of the S&P 500 Index.

“We are in a time of extreme enthusiasm about chip stocks,” said Daniel Morgan, senior portfolio manager at Synovus Trust, which owns Micron shares. “It’s a good time to go and get the US involved in your shares.”

Betting on SK Hynix has been difficult, if not impossible, for the majority of American investors. Like Micron, the second-best performer in the S&P 500 this year with a scorching 242% gain, the company is benefiting from soaring demand for high-bandwidth memory chips. But owning SK Hynix’s South Korea-listed shares outright means off-hours trading in the US.

The other alternative is buying unsponsored American depositary receipts, or ADRs, over the counter. Not only are the unsponsored ADRs performing worse than SK Hynix’s South Korea shares, but liquidity is also severely limited, making trading them a challenge. SK Hynix’s Nasdaq listing, expected on July 10, should change that and improve the company’s lagging valuation.

It’s one of the first things new employees are asked to do: Enroll in a workplace retirement plan. Before doing so, though, they should ask themselves a few basic questions, which can help them make the most of a savings tool that

has minted hundreds of thousands of millionaires.

Qualified retirement-savings plans like 401(k)s—and 403(b)s and 457(b)s in the public and nonprofit sectors—allow workers to save for retirement while deferring taxes. More than 65 million Americans have 401(k) accounts with total assets of $7.9 trillion, according to the Investment Company Institute. 

ET Intelligence Group: One out of every four BSE 100 companies, 23 to be precise, have failed to generate meaningful annualised returns over the past three years, with the number narrowing to 21 on a five-year basis. These companies have yielded 5% or less return over the said periods.

The BSE 100 delivered annualised returns of 9.3% over three years and 9.8% over five years, while the Sensex generated annualised returns of 6.3% and 8.2%, respectively.

Sectorally, the laggards are concentrated in the consumer sector with six companies, followed by five companies from the IT and BFSI sector. Valuations, however, suggest potential as 20 of the 23 stocks trade below their three-year average multiples.

Notably, 12 of these companies are constituents of the Nifty 50. Some of the names include Asian Paints, HDFC Bank, HDFC Life Insurance, Hindustan Unilever (HUL), Infosys, ITC, Reliance Industries (RIL), Tata Consultancy Services (TCS) and Wipro.
For the BFSI sector, the outlook is based on deposit and credit growth, margin stability after rate cuts, and improving asset quality.

For FMCG companies, the growth outlook depends on demand sustainability especially in the rural market. Havells India expects stronger FY27 growth aided by a favourable base, price increases and market share gains after a challenging FY26 due to weak summer season, commodity inflation, and disruptions in West Asia. Growth for Avenue Supermarts is expected to be strong driven by continued store additions, better same-store sales growth, and the resilience of its value-retail model despite rising quick-commerce competition. For ITC, the growth outlook is muted given the higher cigarette tax may impact volume.
IT companies are facing issues such as cautious client spending and AI-led pricing and margin pressure. Analysts expect Tata Consultancy Services and Infosys to fare better than peers in the near term.RIL’s growth is expected to be driven by its consumer and emerging energy businesses, with Jio monetisation, retail expansion, FMCG scale-up and new-energy initiatives.

The semaglutide in the jab and pill mimics the actions of a hormone called GPL-1 (glucagon-like-peptide-1), which is released from the intestine after people eat.

It acts on receptors in the brain that control appetite, making people feel fuller, less hungry and crave food less.

Very common side effects with both include stomach problems, like feeling sick, being sick (vomiting), constipation and diarrhoea.

With the jab, you may get little bit of skin redness, itching or mild swelling where you inject.

Some people on the tablets or injections may experience stomach pain, headaches and tiredness.

More rarely, people can get more serious complications, like low blood sugar, pancreatitis or severe allergic reactions.

It’s worth checking the patient information leaflet for the full details.

Do not take the medication if you are under 18, pregnant or breastfeeding, and make sure you speak to your doctor about any other medical conditions you have or medication you take.